The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 11, 2023

Filed:

Feb. 28, 2020
Applicant:

Macrogenics, Inc., Rockville, MD (US);

Inventors:

Ezio Bonvini, Rockville, MD (US);

Paul A. Moore, Rockville, MD (US);

Jonathan C. Li, Rockville, MD (US);

Leslie S. Johnson, Rockville, MD (US);

Kalpana Shah, Rockville, MD (US);

Assignee:

MACROGENICS, INC., Rockville, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 16/30 (2006.01);
U.S. Cl.
CPC ...
C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C07K 16/283 (2013.01); C07K 16/2809 (2013.01); C07K 16/2815 (2013.01); C07K 16/2827 (2013.01); C07K 16/2878 (2013.01); C07K 16/30 (2013.01); C07K 2317/31 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2318/20 (2013.01); C07K 2319/00 (2013.01);
Abstract

The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Tri-Specific Binding Molecule is preferably characterized in possessing binding domains that permit it to immunospecifically bind to: (1) an epitope of a first Cancer Antigen, (2) an epitope of a second Cancer Antigen, and (3) an epitope of a molecule that is expressed on the surface of an immune system effector cell, and are thus capable of localizing an immune system effector cell to a cell that expresses a Cancer Antigen, so as to thereby facilitate the killing of such cancer cell.


Find Patent Forward Citations

Loading…